Tesamorelin vs MK-677

Overview

Tesamorelin and MK-677 (ibutamoren) both stimulate growth hormone release but through different mechanisms and with vastly different regulatory status. Tesamorelin is FDA-approved for HIV lipodystrophy, while MK-677 remains an investigational compound that never achieved approval despite extensive research.

Key Facts

Aspect	Tesamorelin	MK-677
Class	GHRH analog	GH secretagogue (ghrelin mimetic)
Type	Peptide (injectable)	Small molecule (oral)
Target	GHRH receptor	GHS-R1a (ghrelin receptor)
FDA Status	Approved	Not approved
Brand Name	Egrifta	None (ibutamoren)

Mechanism Comparison

Aspect	Tesamorelin	MK-677
Receptor	GHRH-R	GHS-R1a
Pathway	GHRH signaling	Ghrelin signaling
GH Release	Pulsatile	Sustained/pulsatile
IGF-1 Effect	Increases	Increases significantly
Administration	Injection	Oral

Key Mechanistic Differences

Tesamorelin:

• Mimics natural GHRH
• Maintains physiological GH pulsatility
• Requires injection
• Predictable pharmacokinetics

MK-677:

• Ghrelin receptor agonist
• Long half-life (~24 hours)
• Oral dosing convenient
• Sustained GH/IGF-1 elevation

Evidence Comparison

Aspect	Tesamorelin	MK-677
Human RCTs	Multiple (FDA approved)	Multiple (never approved)
Long-term Data	Yes	Years of trial data
Regulatory Review	FDA approved	Failed to achieve approval
Publication Quality	High	Moderate-high

Why MK-677 Wasn’t Approved

Despite extensive trials, MK-677 never achieved FDA approval:

• No clear therapeutic window
• Metabolic side effects (glucose, appetite)
• Risk/benefit unclear for proposed indications
• Development discontinued by multiple companies

Clinical Data

Tesamorelin (Phase 3)

Population	Finding
HIV lipodystrophy	~18% reduction in visceral fat
IGF-1	Normalized levels
Body composition	Improved trunk fat

MK-677 (Various Trials)

Population	Finding
Healthy elderly	Increased GH, IGF-1 to young adult levels
Hip fracture	No improvement in function
Obesity	Increased hunger, no net benefit
GH deficiency	Increased GH/IGF-1

Side Effect Comparison

Tesamorelin

Effect	Frequency	Notes
Injection site reactions	Common	Local erythema
Peripheral edema	Common	GH-related
Arthralgia	Common	GH-related
Hyperglycemia	Monitor	Less than MK-677

MK-677

Effect	Frequency	Notes
Increased appetite	Very common	Ghrelin effect
Water retention/edema	Very common	Significant
Hyperglycemia	Common	May worsen diabetes
Lethargy	Common	Morning after dosing
Muscle pain	Common	GH-related

Metabolic Effects

Effect	Tesamorelin	MK-677
Glucose tolerance	Monitor	Worsens significantly
Insulin sensitivity	Variable	Decreases
Appetite	Minimal effect	Strongly increases
Weight change	Fat loss	May gain weight (appetite)

MK-677’s metabolic effects are a major limitation.

Administration

Aspect	Tesamorelin	MK-677
Route	Subcutaneous injection	Oral (tablet/liquid)
Convenience	Requires injection	Oral (easy)

Regulatory and Access

Aspect	Tesamorelin	MK-677
FDA Status	Approved	Not approved
Legal Status	Prescription drug	Research chemical
Quality Control	FDA regulated	None
Insurance	May cover (HIV indication)	Not covered
WADA Status	Prohibited	Prohibited

Cost Considerations

Factor	Tesamorelin	MK-677
Approximate Cost	$1,000+/month	Variable (research)
Quality Assurance	Pharmaceutical grade	Unknown
Insurance	Possible for HIV	Never

Key Differences

Factor	Tesamorelin	MK-677
Regulatory status	FDA approved	Never approved
Administration	Injectable	Oral
Mechanism	GHRH-R	GHS-R1a
Glucose effects	Mild concern	Significant concern
Appetite	Minimal	Strong increase
Evidence quality	High	Moderate
Quality control	Regulated	None

Summary

• Tesamorelin is FDA-approved with established safety and efficacy for HIV lipodystrophy
• MK-677 despite extensive research was never approved due to metabolic concerns
• Tesamorelin requires injection; MK-677 is oral (convenience)
• MK-677’s appetite and glucose effects are significant limitations
• Tesamorelin has regulatory oversight; MK-677 quality is uncontrolled
• Both are prohibited in sport

---

This comparison is for educational purposes only. Tesamorelin requires prescription for approved indication. MK-677 is not approved and sold only as a research chemical with uncertain quality. Consult a healthcare provider for treatment decisions.